"
Team:Brasil-SP/TheIssue/OurSolution
From 2014.igem.org
(Difference between revisions)
(Created page with "<b>This page and all it contents are provisional!</b> <p>Here is where we argue how cool and feasible our solution might be. Raising the questions that we'll pursue the answers o...") |
Laiscbrazaca (Talk | contribs) |
||
| Line 1: | Line 1: | ||
| - | < | + | <h3 align="center">Our Solution</h3> |
| - | <p> | + | <p><div align="justify">Several studies support Cystatin C as the best biomarker of renal dysfunction when compared to classical biomarkers (urea nitrogen and serum creatinine), because Cystatin C is very sensitive to changes in GFR. However, the available methods to evaluate the levels of Cystatin C are often very expensive and inefficient, such as the immunofluorescence method. Our solution to this problem is to develop a genetic circuit with the ability to detect different levels of Cystatin C in the blood. When the detectable levels of Cystatin C are higher than the normal, it will lead us to diagnose CKD and other renal dysfunctions in early stages. The genetic circuit is shown in the Figure below and the input information is based on Cystatin C inhibitory activity against cysteine proteases, in this case, cathepsin S.</div></p> |
Revision as of 18:15, 26 September 2014
Our Solution
Several studies support Cystatin C as the best biomarker of renal dysfunction when compared to classical biomarkers (urea nitrogen and serum creatinine), because Cystatin C is very sensitive to changes in GFR. However, the available methods to evaluate the levels of Cystatin C are often very expensive and inefficient, such as the immunofluorescence method. Our solution to this problem is to develop a genetic circuit with the ability to detect different levels of Cystatin C in the blood. When the detectable levels of Cystatin C are higher than the normal, it will lead us to diagnose CKD and other renal dysfunctions in early stages. The genetic circuit is shown in the Figure below and the input information is based on Cystatin C inhibitory activity against cysteine proteases, in this case, cathepsin S.
